Abstract:Polycystic ovary syndrome (PCOS) women with amenorrhea show a higher prevalence of insulin resistance, prediabetes, and dyslipidemia compared to those PCOS women with oligomenorrhea or eumenorrhea. These data suggested the severity of menstrual dysfunction could be used as a readily obtainable marker for the identification of PCOS women at greatest risk of cardiometabolic diseases. Introduction Polycystic ovary syndrome (PCOS) is associated with a wide range of unfavorable cardiometabolic risk factors, including obesity, hypertension, insulin resistance, impaired glucose metabolism, dyslipidemia, and metabolic syndrome. Compared with women with regular menstrual cycles, women with a history of irregular menstrual periods have an increased unfavorable cardiometabolic risk. Recently, the association between the severity of oligomenorrhea and hyperinsulinemia and insulin resistance has been demonstrated. However, evidence linking the severity of menstrual cyclicity with cardiometabolic risk in PCOS women is scarce. Material and Methods This work was a prospective cross‐sectional study. A total of 154 women diagnosed with PCOS by the Rotterdam criteria were recruited from July 2021 to September 2022. PCOS women with eumenorrheic (eumeno group), oligomenorrhea (oligo group), and amenorrhea (ameno group) underwent history and physical examination, gonadal steroid hormone measurement, lipid profile, oral glucose tolerance test, and homeostasis model assessment of insulin resistance. Results A trend toward an increase in unfavorable cardiometabolic risk markers including obesity, hypertension, prevalence of insulin resistance, prediabetes, dyslipidemia, and metabolic syndrome was observed in the ameno group (n = 57) as compared with the eumeno (n = 24) or oligo group (n = 73). A higher prevalence of insulin resistance (odds ratio [OR]: 3.02; 95% confidence interval [CI]: 1.03–8.81) and prediabetes (OR: 3.94; 95% CI: 1.01–15.40) was observed in the ameno group than in the eumeno group, and a higher proportion of dyslipidemia (OR: 2.44; 95% CI: 1.16–5.15) was observed in the ameno group than in the oligo group in the binary logistic regression analysis after adjusting for confounding factors. Conclusions PCOS women with amenorrhea show a higher prevalence of insulin resistance, prediabetes, and dyslipidemia compared with those with oligomenorrhea or eumenorrhea. The severity of menstrual dysfunction could be used as a readily obtainable marker for the identification of PCOS women at greatest risk of cardiometabolic diseases.

Relationship Between Menstrual Cyclomorphosis and Blood Hormone in Polycystic Ovary Syndrome (PCOS) Patients

Association of Serum Thyroid Hormone Levels with Androgen and Metabolic Parameters in Chinese Women with Polycystic Ovary Syndrome: A Retrospective Cross-Sectional Study

The Relationship of Abnormal Menstrual Cycle and Polycystic Ovarian Syndrom.

Study on the Clinical and Endocrine Characteristics of Polycystic Ovary Syndrome with Different Ovarian Morphology

Association of Tumor Markers with Total Testosterone in the Serum of Women with Polycystic Ovary Syndrome

RELATIONSHIP AMONG OVARIAN CHANGES ASSESSED BY TRANSVAGINAL ULTRASONOGRAPHY AND CLINICAL AND ENDOCRINIC FINDINGS OF THE POLYCYSTIC OVARY PATIENTS

Hormonal changes in PCOS

Analysis of Related Prevalent Factors in Polycystic Ovary Syndrome

Alteration of Sera Leptin and Relevant Factors in Patients with Polycystic Ovary Syndrome

Association of severity of menstrual dysfunction with cardiometabolic risk markers among women with polycystic ovary syndrome

Usage of AMH as a determining test of fertility in women with polycystic ovary 2 syndrome (PCOS)

Correlation Between Changes of Mtor Signaling Pathway in Granulosa Cells and Reproductive Endocrine Abnormalities in Polycystic Ovary Syndrome Patients

Association Between Menstrual Patterns and Adverse Pregnancy Outcomes in Patients With Polycystic Ovary Syndrome

Relationship Between Polymorphism of Anti-Mullerian Hormone,anti-Mullerian Hormone Receptor Type Ⅱ and Polycystic Ovary Syndrome

[Features of Morphometry of Ultrasound and Endometrial Histology in the Anovulatory Polycystic Ovary Syndrome Women].

Clinical phenotype and endocrine metabolic parameters in polycystic ovary syndrome patients with and without hyperandrogenemia

Association of classic and 11-oxygenated androgens with polycystic ovaries and menstrual cycle prolongation in infertile women with PCOS

The impact of androgen levels on serum metabolic profiles in patients with polycystic ovary syndrome

[Correlation Between Sex Hormone and Insulin and Various TCM Syndrome Types in Patients with Polycystic Ovarian Syndrome].

The association between melatonin hormone and reproductive hormones in polycystic ovary syndrome: A case–control study

Serum C-reactive Protein and Its Relationship with Clinic Factors in Patients with Polycystic Ovary Syndrome